Roseman University of Health Sciences has been designated as a Research College and University (RCU) in the newly released 2025 Carnegie Classifications, joining an elite group of institutions recognized for their significant research activities. This designation makes Roseman one of only three institutions in Nevada to receive a Carnegie research classification, alongside University of Nevada, Las Vegas (UNLV) and University of Nevada, Reno (UNR), both of which hold R1 status based on levels of research expenditures and doctorate production.
The RCU designation, newly introduced in 2025 by the American Council on Education (ACE) and the Carnegie Foundation for the Advancement of Teaching, recognizes institutions that demonstrate substantial research activity that may not offer extensive doctoral programs. This classification acknowledges institutions that spend more than $2.5 million annually on research. Roseman University faculty research includes cancer, drug discovery and development, drug formulation, and clinical research in dental medicine.
“This recognition validates Roseman University’s commitment to advancing healthcare through innovative research and academic excellence,” said Jeffery Talbot, PhD, Vice President of Research and Dean of the College of Graduate Studies at Roseman University. “Our graduate-level education programs – master’s degrees in biomedical sciences and pharmaceutical sciences – along with our research programs are creating new knowledge and discoveries that contribute to Nevada’s growing biomedical ecosystem.”
Roseman University has made significant investments in research infrastructure, support services and workforce development, including the establishment of a Bioscience Collaborative in Southern Nevada. This initiative, working in partnership with the Las Vegas Global Economic Alliance (LVGEA), the Nevada Governor’s Office of Economic Development (GOED), and BiotechVegas, aims to attract bioscience companies and startups to the region, fostering an environment of innovation and economic growth.
“The Bioscience Collaborative represents our commitment not just to research excellence, but to the economic development of Southern Nevada,” added Dr. Talbot. “By creating a hub for biotechnology and healthtech innovation, we’re offering a comprehensive physical and resource environment where scientists and educators collaborate to conduct research and create new breakthroughs. This helps to diversify our region’s economy while advancing critical healthcare research that benefits our communities.”
The Carnegie Classification’s new RCU classification recognizes institutions that historically may not have been acknowledged for their research contributions. This year, 218 institutions nationwide received the RCU classification. Another 139 received R2 classification for high spending and doctoral production, with $5 million in research spending and 20 research doctorates awarded annually, and 187 institutions received R1 classification, for $50 million in research spending and 70 research doctorates awarded annually.